Anthony Quinn Insider Trading Transactions
Get free email notifications about insider trading for Anthony Quinn.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Anthony Quinn. Anthony Quinn is EVP, CMO & Head of R&D in SYNAGEVA BIOPHARMA CORP ($GEVA) and EVP, CMO, & Head of R&D in SYNAGEVA BIOPHARMA CORP ($GEVA) and Director in Aeglea BioTherapeutics, Inc. ($AGLE) and Interim CEO in Aeglea BioTherapeutics, Inc. ($AGLE) and interim Chief Medical Officer in Aeglea BioTherapeutics, Inc. ($AGLE) and President & CEO in Aeglea BioTherapeutics, Inc. ($AGLE) and Director in Generation Bio Co. ($GBIO) and Director in Kaleido Biosciences, Inc. ($KLDO).
Latest Insider Trading Transactions of Anthony Quinn
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, AGLE, GBIO, KLDO, GEVA
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Feb 19 2021 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Option Exercise | A | 7.35 | 330,000 | 2,425,500 | 330,000 | |
Jul 01 2020 | KLDO | Kaleido Bioscience ... | Quinn Anthony G. | Director | Option Exercise | A | 7.43 | 15,000 | 111,450 | 15,000 | |
Jun 18 2020 | GBIO | Generation Bio Co. | Quinn Anthony G. | Director | Option Exercise | C | 0.00 | 53,654 | 0 | 0 | |
Jun 18 2020 | GBIO | Generation Bio Co. | Quinn Anthony G. | Director | Buy | C | 0.00 | 30,376 | 0 | 72,837 | 42.5 K to 72.8 K (+71.54 %) |
Jun 15 2020 | GBIO | Generation Bio Co. | Quinn Anthony G. | Director | Option Exercise | A | 19.00 | 52,000 | 988,000 | 52,000 | |
May 04 2020 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Buy | P | 4.75 | 165,000 | 783,750 | 538,469 | 373.5 K to 538.5 K (+44.18 %) |
Feb 19 2020 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Option Exercise | A | 8.15 | 301,000 | 2,453,150 | 301,000 | |
Oct 07 2019 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Option Exercise | M | 6.31 | 17,603 | 111,075 | 119,914 | |
Oct 07 2019 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Option Exercise | M | 5.46 | 662 | 3,615 | 0 | |
Oct 07 2019 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Buy | M | 6.31 | 17,603 | 111,075 | 371,908 | 354.3 K to 371.9 K (+4.97 %) |
Oct 07 2019 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Buy | M | 5.46 | 662 | 3,615 | 354,305 | 353.6 K to 354.3 K (+0.19 %) |
Jun 14 2019 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Buy | P | 6.23 | 5,282 | 32,913 | 353,643 | 348.4 K to 353.6 K (+1.52 %) |
Jun 14 2019 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Buy | P | 6.17 | 14,406 | 88,836 | 348,361 | 334 K to 348.4 K (+4.31 %) |
Jun 14 2019 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Buy | P | 6.11 | 12,217 | 74,705 | 333,955 | 321.7 K to 334 K (+3.80 %) |
May 22 2019 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Buy | P | 6.86 | 3,809 | 26,128 | 321,738 | 317.9 K to 321.7 K (+1.20 %) |
May 22 2019 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Buy | P | 6.89 | 13,794 | 94,981 | 317,929 | 304.1 K to 317.9 K (+4.54 %) |
May 22 2019 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Buy | P | 6.56 | 8,989 | 58,923 | 304,135 | 295.1 K to 304.1 K (+3.05 %) |
May 17 2019 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Buy | P | 6.65 | 6,218 | 41,335 | 295,146 | 288.9 K to 295.1 K (+2.15 %) |
May 17 2019 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Buy | P | 6.83 | 5,520 | 37,691 | 288,928 | 283.4 K to 288.9 K (+1.95 %) |
May 17 2019 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Buy | P | 6.76 | 6,256 | 42,269 | 283,408 | 277.2 K to 283.4 K (+2.26 %) |
May 17 2019 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Buy | P | 7.10 | 719 | 5,103 | 277,152 | 276.4 K to 277.2 K (+0.26 %) |
Mar 04 2019 | KLDO | Kaleido Bioscience ... | Quinn Anthony G. | Director | Option Exercise | C | 0.00 | 25,707 | 0 | 0 | |
Mar 04 2019 | KLDO | Kaleido Bioscience ... | Quinn Anthony G. | Director | Buy | C | 0.00 | 12,853 | 0 | 31,603 | 18.8 K to 31.6 K (+68.55 %) |
Feb 08 2019 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Option Exercise | M | 6.31 | 7,433 | 46,902 | 137,517 | |
Feb 08 2019 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Option Exercise | M | 5.46 | 1,323 | 7,224 | 662 | |
Feb 08 2019 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Buy | M | 6.31 | 7,433 | 46,902 | 276,433 | 269 K to 276.4 K (+2.76 %) |
Feb 08 2019 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Buy | M | 5.46 | 1,323 | 7,224 | 269,000 | 267.7 K to 269 K (+0.49 %) |
Dec 10 2018 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Option Exercise | M | 6.31 | 18,584 | 117,265 | 144,950 | |
Dec 10 2018 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Option Exercise | M | 5.46 | 3,306 | 18,051 | 1,985 | |
Dec 10 2018 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Option Exercise | M | 4.11 | 150,000 | 616,500 | 0 | |
Dec 10 2018 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Buy | M | 6.31 | 18,584 | 117,265 | 267,677 | 249.1 K to 267.7 K (+7.46 %) |
Dec 10 2018 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Buy | M | 5.46 | 3,306 | 18,051 | 249,093 | 245.8 K to 249.1 K (+1.35 %) |
Dec 10 2018 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Buy | M | 4.11 | 150,000 | 616,500 | 245,787 | 95.8 K to 245.8 K (+156.60 %) |
Dec 10 2018 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Buy | P | 9.13 | 994 | 9,075 | 95,787 | 94.8 K to 95.8 K (+1.05 %) |
Dec 10 2018 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Buy | P | 6.02 | 2,000 | 12,040 | 94,793 | 92.8 K to 94.8 K (+2.16 %) |
Jul 20 2018 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Option Exercise | A | 9.36 | 50,000 | 468,000 | 50,000 | |
Jul 20 2018 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Option Exercise | A | 9.36 | 75,000 | 702,000 | 75,000 | |
Jul 20 2018 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Option Exercise | A | 9.36 | 75,000 | 702,000 | 75,000 | |
Jul 20 2018 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Option Exercise | A | 9.36 | 300,000 | 2,808,000 | 300,000 | |
Jul 16 2018 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | Interim CEO | Option Exercise | M | 6.31 | 14,866 | 93,804 | 163,534 | |
Jul 16 2018 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | Interim CEO | Option Exercise | M | 7.04 | 24,000 | 168,960 | 0 | |
Jul 16 2018 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | Interim CEO | Buy | M | 6.31 | 14,866 | 93,804 | 92,793 | 77.9 K to 92.8 K (+19.08 %) |
Jul 16 2018 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | Interim CEO | Buy | M | 7.04 | 24,000 | 168,960 | 77,927 | 53.9 K to 77.9 K (+44.50 %) |
Jul 13 2018 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | Interim CEO | Option Exercise | M | 5.46 | 3,307 | 18,056 | 5,291 | |
Jul 13 2018 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | Interim CEO | Buy | M | 5.46 | 3,307 | 18,056 | 53,927 | 50.6 K to 53.9 K (+6.53 %) |
Feb 22 2018 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | Interim CEO | Option Exercise | A | 6.31 | 178,400 | 1,125,704 | 178,400 | |
Feb 20 2018 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | Interim CEO | Option Exercise | M | 5.46 | 15,211 | 83,052 | 8,598 | |
Feb 20 2018 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | Interim CEO | Buy | M | 5.46 | 15,211 | 83,052 | 50,620 | 35.4 K to 50.6 K (+42.96 %) |
Dec 08 2017 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | Interim CEO | Buy | P | 5.07 | 600 | 3,039 | 35,409 | 34.8 K to 35.4 K (+1.72 %) |
Dec 08 2017 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | Interim CEO | Buy | P | 4.99 | 2,800 | 13,967 | 34,809 | 32 K to 34.8 K (+8.75 %) |
Dec 08 2017 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | Interim CEO | Buy | P | 4.92 | 4,888 | 24,072 | 32,009 | 27.1 K to 32 K (+18.02 %) |
Dec 05 2017 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | Director | Buy | P | 4.93 | 5,065 | 24,976 | 27,121 | 22.1 K to 27.1 K (+22.96 %) |
Dec 05 2017 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | Director | Buy | P | 4.98 | 7,956 | 39,624 | 22,056 | 14.1 K to 22.1 K (+56.43 %) |
Dec 05 2017 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | Director | Buy | P | 4.53 | 4,100 | 18,578 | 14,100 | 10 K to 14.1 K (+41.00 %) |
Sep 01 2017 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | Interim CEO | Option Exercise | A | 4.11 | 150,000 | 616,500 | 150,000 | |
Apr 25 2017 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony | interim Chief Medic ... | Option Exercise | A | 7.04 | 24,000 | 168,960 | 24,000 | |
Apr 12 2016 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony | Director | Buy | P | 10.00 | 10,000 | 100,000 | 10,000 | 0 to 10 K |
Jun 23 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO, & Head of ... | Option Exercise | D | 80.35 | 45,000 | 3,615,750 | 0 | |
Jun 23 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO, & Head of ... | Option Exercise | D | 40.74 | 35,000 | 1,425,900 | 0 | |
Jun 23 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO, & Head of ... | Option Exercise | D | 40.32 | 45,000 | 1,814,400 | 0 | |
Jun 23 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO, & Head of ... | Option Exercise | D | 23.00 | 20,497 | 471,431 | 0 | |
Jun 23 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO, & Head of ... | Option Exercise | D | 1.70 | 37,228 | 63,288 | 0 | |
Jun 23 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO, & Head of ... | Option Exercise | D | 0.95 | 5,982 | 5,683 | 0 | |
Jun 23 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO, & Head of ... | Option Exercise | D | 0.95 | 8,964 | 8,516 | 0 | |
Jun 23 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO, & Head of ... | Sell | D | 0.00 | 27,000 | 0 | 0 | 27 K to 0 (-100.00 %) |
Jun 23 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO, & Head of ... | Sell | D | 0.00 | 5,675 | 0 | 27,000 | 32.7 K to 27 K (-17.37 %) |
Jun 23 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO, & Head of ... | Grant | A | 78.87 | 38 | 2,997 | 32,675 | 32.6 K to 32.7 K (+0.12 %) |
Jun 09 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO, & Head of ... | Grant | A | 0.00 | 27,000 | 0 | 32,637 | 5.6 K to 32.6 K (+478.98 %) |
Apr 29 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Option Exercise | M | 1.70 | 10,000 | 17,000 | 37,228 | |
Apr 29 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Sell | S | 110.00 | 10,000 | 1,100,000 | 5,637 | 15.6 K to 5.6 K (-63.95 %) |
Apr 29 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Buy | M | 1.70 | 10,000 | 17,000 | 15,637 | 5.6 K to 15.6 K (+177.40 %) |
Apr 23 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Sell | S | 108.00 | 10,000 | 1,080,000 | 5,637 | 15.6 K to 5.6 K (-63.95 %) |
Apr 17 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Option Exercise | M | 40.74 | 10,000 | 407,400 | 35,000 | |
Apr 17 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Sell | S | 105.00 | 10,000 | 1,050,000 | 15,637 | 25.6 K to 15.6 K (-39.01 %) |
Apr 17 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Buy | M | 40.74 | 10,000 | 407,400 | 25,637 | 15.6 K to 25.6 K (+63.95 %) |
Apr 08 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Option Exercise | M | 23.00 | 9,503 | 218,569 | 20,497 | |
Apr 08 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Option Exercise | M | 0.95 | 10,000 | 9,500 | 8,964 | |
Apr 08 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Sell | S | 93.76 | 29,503 | 2,766,201 | 15,637 | 45.1 K to 15.6 K (-65.36 %) |
Apr 08 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Buy | M | 23.00 | 9,503 | 218,569 | 45,140 | 35.6 K to 45.1 K (+26.67 %) |
Apr 08 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Buy | M | 0.95 | 10,000 | 9,500 | 35,637 | 25.6 K to 35.6 K (+39.01 %) |
Apr 08 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Grant | A | 76.88 | 42 | 3,229 | 25,637 | 25.6 K to 25.6 K (+0.16 %) |
Page: 1